China Biotechnology Service (08037) completed the issuance of convertible bonds with a total principal amount of 35 million USD

2026-02-23 02:03:42

Abstract generation in progress

China Bio-Tech Services (08037) announced that all the conditions precedent set out in the subscription agreement have been satisfied, and the issuance of convertible bonds with a principal amount of US$35 million to the subscribers was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.

Prior to the completion of the convertible bond issuance, there remains an outstanding principal amount of US$6 million of the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HK$1.20 per share.

Since the issuance of the convertible bonds was completed on February 20, 2026, in accordance with the terms and conditions of the 2024 convertible bonds, the conversion price of the 2024 convertible bonds has been adjusted from HK$1.20 per share to HK$1.11 per share, and the maximum number of shares to be issued upon full conversion of the 2024 convertible bonds is 42.4324 million shares, effective from February 20, 2026 (the date of completion of the convertible bond issuance). Apart from the above adjustment, all other terms of the 2024 convertible bonds remain unchanged.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.